-

nihao guest [ sign in / register ]
2021-3-7 19:03:26


Pleguezuelos O, James E, Fernandez A, Lopes V, Ros. Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. NPJ Vaccines. 2020 Mar 13;5(1):22
submited by kickingbird at Feb, 14, 2021 9:47 AM from NPJ Vaccines. 2020 Mar 13;5(1):22

FLU-v, developed by PepTcell (SEEK), is a peptide vaccine aiming to provide a broadly protective cellular immune response against influenza A and B. A randomized, double-blind, placebo-controlled, single-center, phase IIb efficacy and safety trial was conducted. One hundred and fifty-three healthy individuals 18-55 years of age were randomized to receive one or two doses of adjuvanted FLU-v or adjuvanted placebo subcutaneously on days -43 and -22, prior to intranasal challenge on day 0 with the A/California/04/2009/H1N1 human influenza A challenge virus. The primary objective of the study was to identify a reduction in mild to moderate influenza disease (MMID) defined as the presence of viral shedding and clinical influenza symptoms. Single-dose adjuvanted FLU-v recipients (n = 40) were significantly less likely to develop MMID after challenge vs placebo (n = 42) (32.5% vs 54.8% p = 0.035). FLU-v should continue to be evaluated and cellular immunity explored further as a possible important correlate of protection against influenza.

See Also:

    Latest articles in those days:

    [Go Top]    [Close Window]

    Related Pages:
    Learn about the flu news, articles, events and more
    Subscribe to the weekly F.I.C newsletter!


      

    Site map  |   Contact us  |  Term of use  |  FAQs |  粤ICP备10094839号-1
    Copyright ©www.flu.org.cn. 2004-2021. All Rights Reserved. Powered by FIC 4.0.1
      Email:webmaster@flu.org.cn